NEW YORK (GenomeWeb News) – Expression Pathology today announced a collaboration with the University of Texas MD Anderson Cancer Center for the evaluation of the company's Liquid Tissue SRM technology.
Specifically, the deal is for the evaluation of the technology for matching the most appropriate targeted therapies with lung cancer patients.
Financial and other terms were not disclosed.
A new generation of lung cancer therapies that target specific tumor pathways show positive benefits, but in order to help guide drug selection new testing methods are needed, Expression Pathology said. The Rockville, Md.-based firm's Liquid Tissue SRM technology quantifies multiple proteins involved in tumor pathways in formalin-fixed paraffin-embedded tissue.